On January 5, 2023, it was announced that the life science group Sartorius hasextended a strategic collaboration partnership agreement with RoosterBio Inc. to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will seek to provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC)-based exosome production platform that delivers industry-leading yield, purity, and potency. Additionally, this collaboration will focus on the development of comprehensive analytical techniques for the characterization of exosomes and the entire spectrum of extracellular vesicles (EVs) to establish quantitative strategies for quality control of exosome purification intermediates and final drug product. Collaboration between Sartorius and RoosterBio in the field of cell and gene therapy has existed for almost two years for the industrialization of cell-based regenerative cures. It now will take a step further to commercialize the exosome production and purification process using its technologies.